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A B S T R A C T
Purpose: GLUT-1 deﬁciency syndrome (GLUT1DS) is a neurologic disorder manifesting as epilepsy,
abnormal movements, and cognitive delay. The currently accepted treatment of choice is the classic 4:1
ratio ketogenic diet.
Methods: A 2-page survey was distributed to all attendees of a family-centered conference for GLUT1DS
in July 2015. The surveys were completed by parents, collected anonymously, and information analyzed
in a database.
Results: Surveys were received from 92 families, of which 90 (98%) had been treated with dietary
therapies. Diets used were extremely varied: 59 were treated with the classic ketogenic diet (KD),
29 with the Modiﬁed Atkins Diet (MAD), 4 with the Medium-chain Triglyceride (MCT) Diet and 2 with
the low glycemic index treatment. The mean diet duration was 5.5 years (range: 1 month–20 years). Of
those with seizures, 95% of the children had >50% seizure reduction and 80% had >90% seizure
reduction. Children who were seizure-free were currently younger on average (8.2 vs. 11.6 years,
p = 0.01) and slightly younger at GLUT1DS diagnosis (3.8 vs. 5.3 years, p = 0.05). There was an equal
percentage of children seizure-free receiving the KD/MCT Diets compared to the MAD/Low Glycemic
Index Treatment (74% vs. 63%, p = 0.30). The majority (64%) were not receiving anticonvulsants.
Conclusion: This represents the largest series of KD experience in children with GLUT1DS. Nearly all
patients surveyed were on dietary therapies for long durations with reported excellent seizure control,
often without anticonvulsant drugs. Several different ketogenic diets were utilized with similar efﬁcacy.
Early diagnosis and treatment were correlated with success.
 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Glucose-transporter 1 deﬁciency syndrome (GLUT1DS) is a
metabolic disorder resulting from a dominant mutation of the
solute carrier family 2, facilitated glucose transporter member 1
(SLC2A1) gene [1,2]. The result of this haploinsufﬁciency is
decreased brain glucose accumulation and resultant encephalopa-
thy. Clinical manifestations of this disorder are variable but often
include seizures, movement disorders, and cognitive impairments
[2–6].Abbreviations: GLUT1DS, Glucose-1 transporter deﬁciency syndrome; MAD, modi-
ﬁed atkins diet; KD, ketogenic diet; LGIT, low glycemic index treatment; MCT,
medium chain triglyceride.
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1059-1311/ 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reThe current gold standard treatment for GLUT1DS is the classic
ketogenic diet (KD) [2–7]. The KD is a high fat, adequate protein,
low carbohydrate diet in continuous use since 1921 for the
treatment of refractory epilepsy [8]. In an effort to improve diet
tolerance, the modiﬁed atkins diet (MAD), which limits the amount
of carbohydrates consumed to 10–20 g per day, was introduced as
an alternative to the classic KD in 2003 [9]. Both dietary therapies
are helpful in approximately 50% of children who implement them,
and recent evidence also suggests they may be similarly effective
in adults [8,9]. Long-term adverse effects include hypercholester-
olemia, growth disturbance, acidosis, and kidney stones [8].
Since the ﬁrst reports of GLUT1DS in 1991 [1], the classic KD has
been consistently described as the primary adjunctive modality
for treatment of the underlying disorder and its symptomatology
[2–7]. Recognizing that the KD has long-term side effects,
especially relevant for a population that may require it for many
years, alternative treatments have been studied. These include theserved.
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acid [16], and acetazolamide [17].
Until 2012, only mostly small series of 1–10 patients using
dietary therapies had been reported [7,18]. A single-center study
from Columbia University in 2012 described the responses to the
KD in 64 children; 61 of whom had active epilepsy [2]. A large
majority (41/61, 67%) were seizure-free with the KD, mostly within
1 month of treatment [2].
Although recommendations by several GLUT1DS centers have
been made to use the classic high 4:1 ratio (fat: carbohydrate and
protein grams) KD and check serum ketosis [2], in our anecdotal
experience and personal communications with many GLUT1DS
families, this is not universally followed. The use of alternative
diets appeared widespread, value of ketosis questioned, and
duration of dietary therapy variable. The GLUT1 Deﬁciency
Foundation leadership reported many unanswered questions from
parents about optimal dietary therapy management.
2. Methods
A two-page, 21-question survey was created with the
assistance and guidance of the GLUT1 Deﬁciency Foundation
(Supplemental material). Questions included basic demographics
of the child (age of GLUT1DS diagnosis, current age, gender), diet
currently receiving, diet duration, seizure and other neurological
manifestation outcome, adverse effects, and other anticonvul-
sants. Although the survey was primarily focused on dietary
therapies for epilepsy, parents were asked to ﬁll out as much as
they could even if their child had never been treated with a
therapeutic diet. No questions were speciﬁcally asked about
GLUT1 genetic diagnosis, baseline seizure type or frequency, or
EEG ﬁndings. Parents were asked to circle the current diet (and
ketogenic ratio) they were on, and if they had switched between
diets, but other speciﬁc details of ratio changes, carbohydrate
limit, or calorie adjustments over the years were not asked in this
survey.
Surveys were distributed and then collected anonymously at
the July 2015 GLUT1 Deﬁciency Foundation biannual parent
conference held in Orlando, Florida. Those returning a survey were
given a gift card for their participation. One week after this
meeting, electronic versions of the survey were emailed to families
not in attendance of this meeting by Ms. Glenna Steele (GLUT1
Deﬁciency Foundation, USA) and Ms. Emma Williams (Matthews
Friends Charity, United Kingdom). These families were from
countries including primarily United States, United Kingdom, Italy,
Germany, Australia and Japan according to the GLUT1 Deﬁciency
Foundation leadership. Survey information was entered into a
database and analyzed. No surveys were accepted 1 month after
the GLUT1 Deﬁciency Foundation conference.
This survey and research received approval from the Johns
Hopkins University Institutional Review Board. Implied consent
was granted by the survey-based nature of this research.
Categorical data were analyzed using Chi square analysis without
continuity correction. Comparisons of means were analyzed using
a two-tailed t-test. The signiﬁcance level for all tests was p < 0.05.
3. Results
3.1. Overall demographics
Ninety-two families completed the 2-page survey and returned
them for analysis. The majority (51, 55%) completed the survey at
the GLUT1 Deﬁciency Foundation meeting, with the remainder
emailing or faxing their surveys afterwards. Surveys were collected
over a 1 month period. Of these surveys, two families reported
never having been on dietary therapy due to inclusion in C7 oil(triheptanoin) trials [15], they were excluded from further
analysis. No other family ﬁlled out the survey stating that they
had not been on dietary therapy.
There was a large range of subjects included, with a current age
of 1–24 years (mean 9.9 years, median 9 years). GLUT1DS was also
diagnosed at various ages, ranging from 0.1 to 18 years (mean
4.8 years, median 4.0 years). The youngest patient was 1 month at
diagnosis. Forty-seven (52%) were female. There was no difference
in demographics between the patients completing the survey at
the Orlando meeting compared to those who completed it
afterwards.
3.2. Variety of dietary therapies used
Similar to the wide range of subjects, there was an equally
variable list of dietary therapies used by these patients. Families
were asked which diet the patient was currently receiving (or had
just been discontinued if no longer on dietary therapy). The classic
ketogenic diet was being used by 59, with the MAD used by 29 [9],
MCT (medium chain triglyceride) ketogenic diet by four [19], and
the LGIT (low glycemic index treatment) by two [20]. For those
subjects receiving the KD, the ratios were also variable when
reported: 4:1 (n = 16), 3.5:1 (n = 2), 3:1 (n = 20), 2.5:1 (n = 1), 2:1
(n = 13), and 1.5:1 (n = 2). Seventy-eight patients were on the KD at
some point, of which one family did not answer regarding fasting
and admitting during initiation. Of the remainder, 37 (48%) were
fasted at KD onset and 70 (91%) were admitted to the hospital.
The mean age of diet onset was 4.8 years (SD = 3.87; range: 0.1–
18.5 years), with most families reporting starting the diet within
months of the diagnosis of GLUT1DS. Nine patients were already on
dietary therapy when the GLUT1DS diagnosis was made. Children
were started on the KD at a slightly younger age than those initiated
with the MAD or LGIT, 4.1 (SD 3.1) vs. 5.9 (SD = 4.9) years (p = 0.08).
Switching between dietary therapies was common, with
altogether 24 (27%) changing between the KD, MAD and LGIT.
Thirty-three (37%) reported that a discussion occurred between
their family and the neurologist about transitioning from the KD to
the MAD or LGIT, of which 21/33 (64%) in fact made that change. In
fact, of the 31 patients currently on the MAD or LGIT, 19 originally
started with the KD. Five switched from the MAD to the KD,
including three who had originally started with the KD.
3.3. Seizure outcomes
Nine patients were being treated with dietary therapy for
abnormal movements or cognition and did not have epilepsy. Of
the remainder (n = 82), outcomes were excellent with 38 (46%)
reporting seizure freedom, 28 (34%) with 90–99% seizure reduc-
tion, 12 (15%) with 50–89% seizure reduction, and only 4 (5%) with
<50% improvement. Altogether, 95% of the children had >50%
seizure reduction and 80% had >90% seizure reduction, which is
signiﬁcantly higher than most patients with epilepsy treated with
ketogenic diets in the literature [8]. Of the four children with <50%
seizure reduction, two are currently off therapy. Two patients had
improved movements and one had improved cognition despite
lack of seizure control.
Data was analyzed to determine if any factors led to a higher
likelihood of seizure freedom in this population (Table 1). Children
who were seizure-free were currently younger on average (8.2
(SD = 5.7) vs. 11.6 (SD = 5.2) years, p = 0.01) and slightly younger at
diagnosis of GLUT1DS (3.8 (SD = 3.5) vs. 5.3 (SD = 3.4) years,
p = 0.05). In addition, they were less likely to be on anticonvulsant
drugs (13% vs. 57%, p < 0.001), which likely reﬂects neurologist
practice of continuing medications if seizures persisted.
Perhaps most compelling was the lack of any signiﬁcant
difference in outcomes with different diet variants. There was an
Table 1
Factors correlated with presence of reported seizure freedom.
Factor Presence (n = 38) Absence (n = 46) p value
Mean age at GLUT1
diagnosis (years), (SD)
3.8 (3.5) 5.3 (3.4) 0.05
Mean age at diet onset
(years), (SD)
4.0 (3.6) 5.0 (3.5) 0.22
Mean current age
(years), (SD)
8.2 (5.7) 11.6 (5.2) 0.01
KD/MCT currently 28 (74%) 29 (63%) 0.30
4:1 KD 5 (13%) 11 (24%) 0.21
Checking blood ketones 22 (58%) 25 (54%) 0.74
Fasted at diet onset 17 (45%) 20 (43%) 0.91
Gender (female) 19 (50%) 23 (50%) 1.00
On anticonvulsants? 5 (13%) 26 (57%) <0.001
Survey collected at
GLUT1DF meeting?
19 (50%) 24 (52%) 0.84
On carnitine? 23 (61%) 25 (54%) 0.57
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diets when compared to those on the MAD or LGIT (74% vs. 63%,
p = 0.30). Additionally, for those receiving the KD, there was no
difference between those on a 4:1 (strictest) ratio and those with
lower ratios. Five of 16 (31%) on 4:1 ketogenic ratios when using
the KD were seizure-free compared to 21 of 38 (55%) on lower
ketogenic ratios, p = 0.11.
3.4. Antiseizure drugs and supplements
The minority of patients were currently receiving antic-
onvulsants, with only 32 (36%) reporting the use of drugs in
combination with dietary management. A wide variety of antic-
onvulsants were used with the most common being levetiracetam
(n = 8), acetazolamide (n = 6), lamotrigine (n = 6), ethosuximide
(n = 4), and clonazepam (n = 3). Only one child was receiving
valproate (90–99% seizure reduction) and none were treated with
phenobarbital, both theoretic GLUT1 inhibitors [21,22]. Speciﬁc
information about beneﬁts of any particular anticonvulsant was
not questioned in this survey.
All families on dietary therapy were appropriately receiving a
daily multivitamin and calcium. However, 79% were on extra
supplementation beyond that which is advocated by ketogenic diet
experts for routine use [23]. The most common was carnitine [24],
which was used by 52 families, followed by oral citrates in 25
[25]. Additional MCT oil was given by 20 families and several also
wrote in ‘‘extra oils’’.
3.5. Other diet beneﬁts
Recognizing that many families have reported beneﬁts in the
abnormal movements and cognitive dysfunction in GLUT1DS by
using dietary therapy, the survey asked about potential beneﬁts for
abnormal movements speciﬁcally. Seventy-six described having
abnormal movements and all reported beneﬁt. Sixty-four (84%)
agreed that the beneﬁts were ‘‘much better’’ with the remainder
(n = 12) stating they were ‘‘slightly better’’.
3.6. Ketones
Parents were queried regarding their personal practice with
checking for ketosis while on dietary therapy. Thirty-one (34%)
routinely checked blood ketones with home ﬁngerstick devices, 31
(34%) only checked urine acetoacetate using ketone strips.
Nineteen (21%) reported documenting both blood and urine
ketones while the minority (9, 11%) checked neither. Altogether,
50/90 (56%) periodically checked blood ketones, which is not auniversal recommendation of ketogenic diet guidelines but has
been advocated by some centers for GLUT1DS [2,23].
Parents generally believed there was a correlation between
ketones and neurologic function. Twenty-four families did not
have active seizures, so were unable to assess this correlation, but
in the remainder with at least periodic seizures, 44/66 (67%)
reported a correlation between seizures and the level of ketosis, 7
(11%) saw no correlation, and 15 (23%) were unsure. There was no
increased likelihood of seizure freedom in those who checked
blood ketones compared to those who did not, 58% vs. 54%,
p = 0.74. Interestingly, the perceived correlation between seizures
and other neurologic manifestations (stated as ‘‘abnormal move-
ments/learning/behavior’’) was even stronger, with 65/90 (72%)
reporting a correlation, 7 (8%) without correlation, and 18 (20%)
unsure.
3.7. Puberty
Twenty-two children were reported as undergoing puberty
while receiving dietary therapy in this cohort. Fourteen (64%) had a
reported ‘‘change’’ in seizure frequency, although the survey did
not specify if seizures improved or worsened. The remainder had
either no change in seizures or the family was unsure. Eleven (50%)
had a decrease in ketosis level during this transition into
adolescence.
3.8. Diet discontinuation
The total duration of dietary therapy in this population was
signiﬁcantly longer overall than the traditional 2 years recom-
mended by most experts [23]. The mean diet duration was
5.6 years (SD = 4.5; range: 1 month–20 years). Three children were
no longer on dietary therapy, current age range 4–17 years.
Parents were asked if their neurologist had ever discussed with
them the possibility of ever discontinuing dietary therapy
altogether in the future. Twenty-one (23%) recalled that conversa-
tion, but more (37%) were told the opposite, that dietary therapy
was a lifelong treatment for GLUT1DS. Thirty-six (40%) did not
recall such a discussion. When queried about their personal beliefs,
eight (9%) planned to come off the diet (including the three who
did), 22 (24%) had no plans to ever discontinue dietary therapy, and
the majority (60, 67%) were unsure about eventually stopping their
child’s diet.
3.9. Side effects
Parents were asked to write in any adverse effects that occurred
during their child’s time on dietary therapy. Fifty-nine (66%)
reported difﬁculties but none stated this was a reason for
discontinuation (and as stated previously, only three have
discontinued the diet for inefﬁcacy). Most of these side effects
were gastrointestinal system related, including constipation
(n = 24), weight loss or hunger (n = 6), and gastroesophageal
reﬂux (n = 5). Only two children had kidney stones, two had
reported acidosis, and one with elevated serum cholesterol levels.
Several parents commented on the diet being restrictive or difﬁcult
to adhere to. Many shared personal tips for improving compliance
with dietary therapy over many years.
4. Discussion
While it may be impossible to know the exact percentage of
GLUT1DS patients who are receiving dietary therapy, we believe
that we have reached a signiﬁcant number of patients with the
help of the GLUT1DS Foundation and the use of email and various
social media platforms. Only two out of the 92 respondents
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due to triheptanoin use. Because this survey focused mainly on
dietary therapy, some families not on dietary therapy may have
chosen not to respond, yet we believe this suggests the vast
majority are on diets.
Of those that responded and are receiving dietary treatments,
there was an overwhelmingly positive response for control of both
seizures and abnormal movements. The majority of patients were
able to achieve this success without the use of anticonvulsants and
sustain this level of control for many years. These results from
multiple patients worldwide is similar to the single-center results
from Columbia University, with the majority achieving >90%
seizure reduction and many off anticonvulsant drugs [2].
Those who began dietary treatment at a younger age had better
outcomes overall. Those who had an earlier diagnosis also tended to
achieve better results than their older counterparts. This powerful
ﬁnding conﬁrms previous hypotheses about GLUT1 treatment
and suggests that early detection and rapid implementation of
dietary therapy may be important in the treatment of GLUT1DS
[2,7,13]. Genetic screening for the SLC2A1 gene has helped expedite
the earlier diagnosis of GLUT1DS and may lead to sooner dietary
interventions [5,7]. Additionally, recognition of early onset absence
epilepsy [26] and other movement disorders as features of GLUT1DS
may also lead to earlier detection. While alternative treatments,
such as the use of triheptanoin, are under clinical investigation, we
feel strongly that implementation of dietary therapy should not be
delayed after a diagnosis has been made [15,27].
Although these results and other studies have established
dietary therapy as the gold standard of treatment, the speciﬁc diet
that one should use is not as clear. As we suspected, diets used by
families varied widely. Many families were using alternative diets
such as the MAD and the LGIT. Even among those using the classic
KD, ratios varied widely and ranged from 4:1 to 2:1 and included
the MCT diet. Outcomes reported were nearly identical among all
diets and ratios. We were surprised that a slight trend towards
improved seizure-free rates were seen in those NOT on a 4:1, but
this may still reﬂect the modest sample size in this survey. Our
survey results, although parent-reported and retrospective in
nature, conﬁrm previous reports that consideration could be made
for using alternative diets in the GLUT1DS population, especially in
the long-term, to improve side effects and tolerability when
deemed medically appropriate [10–13]. In our clinical experience
at our institutions, we have both started and transitioned GLUT1DS
patients to these alternative diets during adolescence with
preliminarily good results. In a few patients who have had
worsening of seizures, restarting a high ratio KD has led to rapid
resumption of prior seizure control.
This survey highlights multiple areas of future research. The
majority of families reported checking serum ketones and often
noted a correlation between ketone levels and seizure control.
However, those who checked serum ketone levels were no more
likely to achieve seizure freedom than those how did not. A
prospective trial comparing blood with urine monitoring might be
of importance, especially as daily ﬁngersticks for a child with a
disability can be burdensome and expensive to a family. This
survey also indicated that puberty may be a time of concern for
patients with GLUT1DS on diets. There are indications that this
may be a time of change for all dietary therapy patients regardless
of etiology as well as for epilepsy patients in general [28]. Dietary
therapies appeared overall similar; therefore a prospective trial of
either lower ratio KD or the MAD for newly-diagnosed GLUT1DS
(with an ability to switch to a more restrictive KD allowed) may be
justiﬁed. In addition, a prospective trial including EEG would avoid
any placebo effect or over-estimation of the true beneﬁt of dietary
therapy (or any version of this treatment). Finally, patients were
receiving a wide variety of dietary supplements. These supple-ments were likely intended to boost ketosis as well as to improve
tolerability and reduce side effects. Although carnitine was used by
half, and has been suggested by some centers for empiric use, these
results showed no preferential outcomes [2,24]. Trials of these
supplements in children with GLUT1DS on dietary therapy
therefore, especially MAD and LGIT, are warranted. Lastly, even
though this is the largest cohort of GLUT1DS patients reported with
dietary therapy, future prospective studies with larger numbers
may allow for more deﬁnitive statements to be made about
statistical correlations and beneﬁts of individual diets.
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